Compare Coursera Inc (COUR) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coursera Inc vs Charles River Laboratories Intl. Inc — how do they compare? Coursera Inc trades at $5.62 (market cap $1.50B), while Charles River Laboratories Intl. Inc trades at $283.19 (market cap $13.46B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 9× Coursera Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Coursera Inc nearer its low. Which is the better fit depends on your goals.
| COUR | CRL | |
|---|---|---|
Market Cap | $1.50B | $13.46B |
Sector | Consumer Staples | Health |
52-Week High | $12.20 | $282.00 |
52-Week Low | $5.09 | $145.57 |
Enterprise Value | $759.54M | $16.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COUR trades at $5.76, down 0.86% today, with a neutral technical signal. Revenue grew to $757.5M in 2025, but net income remains negative at -$51M. The company recently beat Q2 2026 EPS estimates at $0.17 versus $0.10 expected. Positive cash flow from operations of $108.7M in 2025 supports liquidity, while a $100M investment in LearnVector highlights strategic AI focus.
Outlook is mixed: analyst consensus is bullish with a $7.70 price target (34% upside), but persistent losses and competitive pressures pose risks. The stock offers growth potential if profitability improves, yet high SG&A costs and integration challenges from the Udemy acquisition require monitoring.
Charles River Laboratories (CRL) trades at $277.00, up 3.56% on the day and near its 52-week high of $277.07, reflecting strong bullish momentum. The stock exhibits positive technical signals with moving averages indicating an uptrend, though oscillators suggest overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $3.02, beating estimates, and raised full-year guidance, yet faces profitability challenges with a negative net income margin of -5.96% and elevated valuation ratios like a P/E of 684.85. Recent news highlights improved biotech demand and institutional buying interest.
The outlook for CRL is cautiously optimistic, driven by earnings beats and raised guidance, but high valuation and weak profitability pose risks. Investment opportunity lies in sustained demand for drug development services, while risks include margin pressure, debt levels, and sensitivity to biotech funding cycles. The stock's proximity to all-time highs warrants monitoring for pullbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
